Riskpilot← Back to searchSign inGet full accessMEDILASER AS
ASActiveOrg 989053698Korsegata 8, 6002 ÅlesundWholesale of pharmaceutical and medical goods · NACE 4646Est. 20060 employees
Revenue 2025
NOK 5,7M
+5% vs 2024
EBITDA margin
29.2%
+12% vs 2024
Equity ratio
42.3%
Financial strength
Net profit 2025
NOK 1,3M
+21% vs 2024
| Revenue | NOK 5,7M | +5% |
| EBITDA | NOK 1,7M | +12% |
| Net profit | NOK 1,3M | +21% |
| Total assets | NOK 3,7M | +1% |
| Equity | NOK 1,6M | +10% |
| Employees | 0 | — |
Legal name
MEDILASER AS
Org number
989053698
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
9. januar 2006
Share capital
NOK 400 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Å engasjere seg i aktiviteter som forventes å gi økonomisk avkastning. Selskapet kan engasjere seg i andre virksomheter, enten direkte eller ved kjøp av aksjer, parter eller på annen måte.
Address
Korsegata 8, 6002 Ålesund
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 5 243 | 5 178 | 4 993 | 5 432 | 5 716 |
| Staff expenses | −1 | −1 | −4 | −2 | −3 |
| EBITDA | 1 850 | 1 589 | 1 357 | 1 492 | 1 668 |
| Depreciation & amort. | −298 | −187 | −147 | −50 | −22 |
| EBIT | 1 552 | 1 402 | 1 211 | 1 442 | 1 645 |
| Net financials | −1 | −0 | 28 | 55 | 59 |
| Profit before tax | 1 551 | 1 402 | 1 239 | 1 497 | 1 705 |
| Tax | 341 | 308 | 273 | 390 | 363 |
| Net profit | 1 210 | 1 093 | 967 | 1 106 | 1 341 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 910 | 3 127 | 3 398 | 3 672 | 3 713 |
| Equity | 1 564 | 1 758 | 1 524 | 1 431 | 1 572 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 346 | 1 370 | 1 874 | 2 242 | 2 141 |
| Total debt | 2 346 | 1 370 | 1 874 | 2 242 | 2 141 |
EBITDA margin
29.2%
This company
15.8%
Market median
+85% vs market
20212025
Equity ratio
42.3%
This company
38.2%
Market median
+11% vs market
20212025
Return on equity
85.3%
This company
18.4%
Market median
+364% vs market
20212025
Net profit margin
23.5%
This company
8.1%
Market median
+190% vs market
20212025
Asset turnover
1.54×
This company
1.12×
Market median
+37% vs market
20212025
Debt / equity
1.36×
This company
0.62×
Market median
-119% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TS Chief Executive Officer | Chief Executive Officer | 2015 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2015 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 51% | 51% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Solaris B As
MEDILASER AS Board members of MEDILASER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Trine Skarbø | Chief Executive Officer | 0 companies |
| Olga Joanna Wysocka | Chairman | 0 companies |